Diflorasone Diacetate Ointment 0.05% versus Betamethasone Dipropionate Ointment 0.05% in Moderate-Severe Plaque-Type Psoriasis

Shupack, Jerome L.; Jondreau, Lorrie; Kenny, C.; Stiller, Matthew J.

doi:10.1159/000247323

Cited by 29 publications

(20 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The shortest length of treatment was one week. Treatment success with betamethasone dipropionate 0.05 mg/g ointment 2X/daily was seen after two to three weeks; marked improvement was seen after only one week [117, 124, 137]. The efficacy of beta‐ methasone dipropionate is confirmed by all studies; studies report significant improvement or complete clearance after two to four weeks in 25 – 77.8%[126, 141].…”

Section: Topical Therapymentioning

confidence: 99%

S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

Nast

Boehncke

Mrowietz

et al. 2012

J Deutsche Derma Gesell

250

247

View full text Add to dashboard Cite

Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1.5% to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, surveys have shown that patients still do not received optimal treatments. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologi sche Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. They were first published in 2006 and updated in 2011. The Guidelines focus on induction therapy in cases of mild, moderate and severe plaque-type psoriasis in adults including systemic therapy, UV therapy and topical therapies. The therapeutic recommendations were developed based on the results of a systematic literature search and were finalized during a consensus meeting using structured consensus methods (nominal group process).

show abstract

Section: Topical Therapymentioning

confidence: 99%

S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

Nast

Boehncke

Mrowietz

et al. 2012

J Deutsche Derma Gesell

250

247

View full text Add to dashboard Cite

show abstract

“…Ten grade A 2 studies on topical steroid monotherapy were included [116][117][118][119][120][121][122][123][124][125], 17 grade B studies [104,[126][127][128][129][130][131][132][133][134][135][136][137][138][139][140][141], and two grade C studies [142,143]. Ten grade A 2 studies on topical steroid monotherapy were included [116][117][118][119][120][121][122][123][124][125], 17 grade B studies [104,[126][127][128][129][130][131][132][133][134]…”

Section: Efficacymentioning

confidence: 99%

S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011

Nast

Boehncke

Mrowietz

et al. 2011

J Deutsche Derma Gesell

155

View full text Add to dashboard Cite

“…data]. The corticosteroid chosen was betamethasone dipropionate, as it is widely used for the treatment of psoriasis and its efficacy and safety are well established [12, 13, 14]. Two large studies [15, 16]have demonstrated the superior efficacy of this new combination treatment used twice daily compared to twice daily application of its individual active components.…”

Section: Introductionmentioning

confidence: 99%

A New Calcipotriol/Betamethasone Dipropionate Formulation (Daivobet<sup>TM</sup>) Is an Effective Once-Daily Treatment for Psoriasis vulgaris

et al. 2002

View full text Add to dashboard Cite

Background: Topical corticosteroids and calcipotriol have been used separately for many years to treat psoriasis. A new combination ointment has been formulated, which contains both calcipotriol and the corticosteroid betamethasone dipropionate. Objective: To compare the combination ointment with betamethasone dipropionate ointment, calcipotriol ointment and ointment vehicle in patients with psoriasis vulgaris. Methods: 1,603 patients were randomised to one of the 4 double-blind treatments used once daily for 4 weeks. Results: Themean percentage change in the PASI at the end of treatment was –71.3 (combination), –57.2 (betamethasone), –46.1 (calcipotriol) and –22.7 (vehicle). The mean difference of combination minus betamethasone was –14.2 (95% CI: –17.6 to –10.8, p < 0.001), of combination minus calcipotriol –25.3 (95% CI: –28.7 to –21.9, p < 0.001) and of combination minus vehicle –48.3 (95% CI: –53.2 to –43.4, p < 0.001). 6.0% of patients (combination) reported local adverse reactions compared to 4.9% (betamethasone), 11.4% (calcipotriol) and 13.6% (vehicle). Conclusion: Calcipotriol/betamethasone dipropionate combination ointment used once daily is well tolerated and more effective than either active constituent used alone.

show abstract

Diflorasone Diacetate Ointment 0.05% versus Betamethasone Dipropionate Ointment 0.05% in Moderate-Severe Plaque-Type Psoriasis

Cited by 29 publications

References 11 publications

S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011

A New Calcipotriol/Betamethasone Dipropionate Formulation (Daivobet<sup>TM</sup>) Is an Effective Once-Daily Treatment for Psoriasis vulgaris

Contact Info

Product

Resources

About